Immuneering Corporation (IMRX)
| Market Cap | 48.63M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -53.47M |
| Shares Out | 29.65M |
| EPS (ttm) | -1.88 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 338,325 |
| Open | 1.730 |
| Previous Close | 1.560 |
| Day's Range | 1.600 - 1.730 |
| 52-Week Range | 1.380 - 11.920 |
| Beta | -0.89 |
| Analysts | Buy |
| Price Target | 15.14 (+823.17%) |
| Earnings Date | May 14, 2024 |
About IMRX
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridg... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for IMRX stock is "Buy." The 12-month stock price forecast is $15.14, which is an increase of 823.17% from the latest price.
News
IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models
- Preclinical data presented at AACR demonstrate that combining IMM-1-104 with chemotherapies used in the treatment of first-line pancreatic cancer yielded deeper and more durable tumor growth inhibit...
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 03, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Deep Cyclic Inhibitor of the MAPK pathway demonstrated strong tumor growth inhibition in preclinical studies of RAF or RAS mutant tumors, both as monotherapy and in combination - - Phase 1 portion o...
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors
- IMM-1-104 has been well-tolerated, demonstrating the potential for a differentiated safety profile - - 100% suppression of acquired RAS alterations was observed in evaluable patients profiled for ct...
Immuneering Appoints Thomas J. Schall, Ph.D.
CAMBRIDGE, Mass., March 12, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...
Immuneering Doses First Patient in Phase 2a Clinical Trial of IMM-1-104 in RAS-mutant Solid Tumors
- First patient dosed with IMM-1-104 in combination with modified gemcitabine plus nab-paclitaxel for first-line treatment of pancreatic ductal adenocarcinoma (PDAC) -
Biotech/Oncology Stocks Targeting the Pancreatic Cancer Market - A Race Worth Winning
Vancouver, Kelowna and Delta, British Columbia--(Newsfile Corp. - March 6, 2024) - Investorideas.com, a global investor news source covering biotech and pharma stocks issues a sector snapshot on devel...
Immuneering to Present Preclinical Data on Universal-RAS Program IMM-1-104 at American Association for Cancer Research Annual Meeting 2024
CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...
Immuneering to Participate in the Cowen 44th Annual Health Care Conference
CAMBRIDGE, Mass., March 04, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize universal-RAS/RAF medicines for broa...
Immuneering Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
- Topline data from the Phase 1 portion of Phase 1/2a trial of IMM-1-104 expected in March 2024 - - Dosing of first patient in the expanded Phase 2a portion of Phase 1/2a trial of IMM-1-104 expected i...
Immuneering Receives FDA Fast Track Designation for IMM-1-104 in Pancreatic Cancer
– Fast Track designation has the potential to accelerate lead asset IMM-1-104's path to U.S. FDA submission for pancreatic ductal adenocarcinoma –
Immuneering Announces Participation in February Investor Conferences
CAMBRIDGE, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop universal-RAS/RAF medicines for broad populations of ca...
Immuneering Announces FDA Clearance of IND Application for Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations
- Dosing of first patient in the Phase 1/2a clinical trial expected in early 2024 - CAMBRIDGE, Mass., Dec. 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncolog...
Immuneering to Present at the 35th Annual Piper Sandler Healthcare Conference
CAMBRIDGE, Mass., Nov. 20, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop medicines for broad populations of cancer patients with...
Immuneering Reports Third Quarter 2023 Financial Results and Provides Business Updates
-Dose evaluation portion of IMM-1-104 Phase 1/2a trial approximately two-thirds enrolled; Immuneering's recommendation for a Phase 2 dose expected in early 2024 -
Immuneering Presents Preclinical Data Demonstrating Encouraging Anti-Tumor Activity for IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC Conference
– Expanded benchmarking of IMM-1-104 as a single agent across more than 190 patient-aligned models in humanized 3D-tumor growth assays demonstrated high sensitivity in a wide range of MAPK-driven tumo...
Immuneering to Present Preclinical Data on IMM-1-104 and IMM-6-415 at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an init...
Immuneering to Present at the Morgan Stanley Healthcare Conference
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ini...
Immuneering Reports Second Quarter 2023 Financial Results and Provides Business Updates
- Positive initial pharmacokinetic, pharmacodynamic and safety data presented at American Association for Cancer Research (AACR) annual meeting, with IMM-1-104 demonstrating Cmax, half-life, and pERK/...
Immuneering Completes Dose Escalation in the IMM-1-104 Phase 1 Clinical Trial for RAS-Mutant, Advanced Solid Tumors
- No dose limiting toxicities observed with IMM-1-104 up to 320 mg once daily during the Phase 1a dose escalation portion of ongoing clinical study -
Immuneering to Present at the Jefferies Healthcare Conference
CAMBRIDGE, Mass., May 30, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initi...
Immuneering Reports First Quarter 2023 Financial Results and Provides Business Updates
- Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program presented at American Association for Cancer Research (AACR) annual meeting -
Immuneering Announces $30 Million Underwritten Offering
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX) (“Immuneering”), a clinical-stage oncology company developing medicines for broad populations of cancer pati...
Immuneering Announces Positive Initial Phase 1 Pharmacokinetic, Pharmacodynamic and Safety Data for IMM-1-104 Universal-RAS Program; Accelerates Study Timeline
CAMBRIDGE, Mass., April 18, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ini...
Immuneering to Present at the 22nd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 12, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an ini...